Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.

ABSTRACT:

Background

Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined.

Objective

To compare valganciclovir prophylaxis with polymerase chain reaction-guided preemptive therapy.

Design

Randomized, double-blind trial. (ClinicalTrials.gov: NCT00016068).

Setting

Multicenter trial.

Patients

184 recipients of hematopoietic cell transplantation (HCT) who were at high risk for late CMV disease (95 patients received valganciclovir and 89 received placebo).

Intervention

6 months of valganciclovir (900 mg/d) or placebo. Patients with polymerase chain reaction positivity at 1000 copies/mL or greater or a 5-fold increase over baseline were treated with ganciclovir or valganciclovir (5 mg/kg or 900 mg twice daily, respectively).

Measurements<

SUBMITTER: Boeckh M 

PROVIDER: S-EPMC4465336 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature